SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Van Asperen Christi J.)
 

Sökning: WFRF:(Van Asperen Christi J.) > Evaluation of multi...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005869naa a2200733 4500
001oai:lup.lub.lu.se:020b4257-1f13-4bdf-8e1d-74a43468abee
003SwePub
008210826s2021 | |||||||||||000 ||eng|
0247 a https://lup.lub.lu.se/record/020b4257-1f13-4bdf-8e1d-74a43468abee2 URI
0247 a https://doi.org/10.1038/s41523-021-00301-02 DOI
040 a (SwePub)lu
041 a engb eng
042 9 SwePub
072 7a art2 swepub-publicationtype
072 7a ref2 swepub-contenttype
1001 a Bayani, Janeu Ontario Institute for Cancer Research,University of Toronto4 aut
2451 0a Evaluation of multiple transcriptomic gene risk signatures in male breast cancer
264 c 2021-07-26
264 1b Springer Science and Business Media LLC,c 2021
520 a Male breast cancer (BCa) is a rare disease accounting for less than 1% of all breast cancers and 1% of all cancers in males. The clinical management is largely extrapolated from female BCa. Several multigene assays are increasingly used to guide clinical treatment decisions in female BCa, however, there are limited data on the utility of these tests in male BCa. Here we present the gene expression results of 381 M0, ER+ve, HER2-ve male BCa patients enrolled in the Part 1 (retrospective analysis) of the International Male Breast Cancer Program. Using a custom NanoString™ panel comprised of the genes from the commercial risk tests Prosigna®, OncotypeDX®, and MammaPrint®, risk scores and intrinsic subtyping data were generated to recapitulate the commercial tests as described by us previously. We also examined the prognostic value of other risk scores such as the Genomic Grade Index (GGI), IHC4-mRNA and our prognostic 95-gene signature. In this sample set of male BCa, we demonstrated prognostic utility on univariate analysis. Across all signatures, patients whose samples were identified as low-risk experienced better outcomes than intermediate-risk, with those classed as high risk experiencing the poorest outcomes. As seen with female BCa, the concordance between tests was poor, with C-index values ranging from 40.3% to 78.2% and Kappa values ranging from 0.17 to 0.58. To our knowledge, this is the largest study of male breast cancers assayed to generate risk scores of the current commercial and academic risk tests demonstrating comparable clinical utility to female BCa.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
7001 a Poncet, Coralieu European Organisation for Research and Treatment of Cancer4 aut
7001 a Crozier, Cherylu Ontario Institute for Cancer Research4 aut
7001 a Neven, Anouku European Organisation for Research and Treatment of Cancer4 aut
7001 a Piper, Tammyu University of Edinburgh4 aut
7001 a Cunningham, Carrieu University of Edinburgh4 aut
7001 a Sobol, Monikau University of Edinburgh4 aut
7001 a Aebi, Stefanu SAKK Coordinating Center4 aut
7001 a Benstead, Kimu Cheltenham General Hospital4 aut
7001 a Bogler, Oliveru University of Texas4 aut
7001 a Dal Lago, Lissandrau Institut Jules Bordet4 aut
7001 a Fraser, Judith4 aut
7001 a Hilbers, Florentineu Breast International Group4 aut
7001 a Hedenfalk, Ingridu Lund University,Lunds universitet,Bröst- och ovarialcancer,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Bröst/ovarialcancer,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breast and Ovarian Cancer Genomics,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Breast/ovarian cancer,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)onk-ifa
7001 a Korde, Larissau University of Washington4 aut
7001 a Linderholm, Barbrou Sahlgrenska University Hospital4 aut
7001 a Martens, Johnu Erasmus University Medical Center4 aut
7001 a Middleton, Laviniau University of Texas4 aut
7001 a Murray, Melissau Memorial Sloan-Kettering Cancer Center4 aut
7001 a Kelly, Catherine4 aut
7001 a Nilsson, Cecilia4 aut
7001 a Nowaczyk, Monika4 aut
7001 a Peeters, Stephanie4 aut
7001 a Peric, Aleksandrau European Organisation for Research and Treatment of Cancer4 aut
7001 a Porter, Peggyu University of Washington4 aut
7001 a Schröder, Carolienu University Medical Center Groningen4 aut
7001 a Rubio, Isabel T.u Bellvitge University Hospital-IDIBELL4 aut
7001 a Ruddy, Kathryn J.u Mayo Clinic Minnesota4 aut
7001 a van Asperen, Christiu Leiden University Medical Centre4 aut
7001 a Van Den Weyngaert, Danielle4 aut
7001 a van Deurzen, Carolienu Erasmus University Medical Center4 aut
7001 a van Leeuwen-Stok, Eliseu Dutch Breast Cancer Research Group (BOOG)4 aut
7001 a Vermeij, Joanna4 aut
7001 a Winer, Ericu Dana-Farber Cancer Institute4 aut
7001 a Giordano, Sharon H.u University of Texas4 aut
7001 a Cardoso, Fatima4 aut
7001 a Bartlett, John M.S.u University of Toronto,University of Edinburgh4 aut
7102 a Ontario Institute for Cancer Researchb University of Toronto4 org
7730 t npj Breast Cancerd : Springer Science and Business Media LLCg 7:1q 7:1x 2374-4677
8564 u http://dx.doi.org/10.1038/s41523-021-00301-0x freey FULLTEXT
8564 u https://www.nature.com/articles/s41523-021-00301-0.pdf
8564 8u https://lup.lub.lu.se/record/020b4257-1f13-4bdf-8e1d-74a43468abee
8564 8u https://doi.org/10.1038/s41523-021-00301-0

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy